Larimar Therapeutics, INC

Larimar Therapeutics reported strong Q2 2026 results, highlighting progress in its rolling BLA submission for nomlabofusp and positive long-term study data for Friedreich's Ataxia.

Larimar Therapeutics announced the submission of the first module of its Biologics License Application for nomlabofusp and positive long-term data from its open-label study in Friedreich's Ataxia.

Larimar Therapeutics held its 2026 Annual Meeting of Stockholders, with key proposals including director elections, executive compensation, and an increase in authorized shares receiving majority approval.

Larimar Therapeutics announced Q1 2026 financial results and operational highlights, including plans to initiate a rolling BLA submission for nomlabofusp in June 2026, with $200.4 million in cash providing runway into Q2 2027.

Larimar Therapeutics announced its Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation for nomlabofusp and a strengthened balance sheet.

Larimar Therapeutics, Inc. announced the pricing of a public offering of 23 million shares of common stock at $5.00 per share, expecting net proceeds of approximately $107.6 million.

Larimar Therapeutics reports progress on its nomlabofusp Biologics License Application submission and positive long-term safety data, while acknowledging substantial operating losses and the necessity for future capital raises.

Larimar Therapeutics reports Q1 2026 results, highlighting progress in nomlabofusp development for Friedreich's Ataxia and a strong cash position following recent financings.

Larimar Therapeutics, Inc. reported increased operating losses in Q3 2025 but highlighted positive clinical data for nomlabofusp in Friedreich's ataxia and plans for a Q2 2026 BLA submission.

Larimar Therapeutics reported increased net losses and cash burn in its second quarter, while making significant clinical and regulatory progress for its lead Friedreich's ataxia drug candidate, nomlabofusp.

Larimar Therapeutics' Q1 2025 report highlights ongoing clinical trials for nomlabofusp in Friedreich's ataxia, including positive FDA feedback and plans for a Phase 3 study, alongside increased R&D spending and a net loss of $29.3 million.

Larimar Therapeutics reported its third quarter 2024 financial results, highlighting progress in its nomlabofusp clinical program and ongoing open label extension study.

Larimar Therapeutics reports significant progress in its nomlabofusp clinical program for Friedreich's ataxia, including positive OL study data and key regulatory designations, while securing $107.6 million in new funding.

Larimar Therapeutics advances nomlabofusp, a potential treatment for Friedreich's ataxia, with positive clinical data and a targeted BLA submission by the end of 2025.

Larimar Therapeutics' 10-K filing details a non-qualified stock option grant, updates on clinical trials for nomlabofusp, and outlines financial strategies for the company's future.

Larimar Therapeutics Director Thomas Edward Hamilton reported the acquisition of 50,000 shares of common stock.

Director Jonathan S. Leff, representing Deerfield Management, was granted 55,150 stock options in Larimar Therapeutics.

Director Jonathan S. Leff was granted 55,150 stock options in Larimar Therapeutics, Inc. as part of his board service.

Larimar Therapeutics, Inc. reports that Director Joseph Truitt was granted stock options on May 19, 2026, with vesting contingent on continued service.

Larimar Therapeutics Director Thomas Frank E. acquired 55,150 stock options with an exercise price of $3.33, vesting on May 19, 2027, or the next annual meeting.

Larimar Therapeutics Director Thomas Edward Hamilton acquired 55,150 stock options with an exercise price of $3.33, vesting on May 19, 2027, or the next annual meeting.

Larimar Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 19, 2026, with key proposals including director elections, executive compensation, auditor ratification, and a significant increase in authorized shares.

Larimar Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 13, 2025, featuring proposals for director election, executive compensation approval, and auditor ratification.

Larimar Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 29, 2024, to vote on director elections, executive compensation, auditor ratification, and corporate governance matters.

Deerfield Management Company and its affiliated funds increased their beneficial ownership in Larimar Therapeutics, Inc. to 34.41% through a $25 million share purchase in a recent offering.

Deerfield Management and its affiliated funds have increased their beneficial ownership in Larimar Therapeutics, Inc. to 35.81% of common stock after acquiring an additional 9.37 million shares for $30 million in a recent underwritten offering.

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Larimar Therapeutics, Inc. common stock as of March 31, 2026.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 3.5% beneficial ownership stake in Larimar Therapeutics, Inc.

Blue Owl Capital Holdings LP has increased its beneficial ownership in Larimar Therapeutics, Inc. to 9.99% of common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a shared beneficial ownership of 5.8% of Larimar Therapeutics, Inc. common stock.

Opaleye Management, L.P., and James Silverman have disclosed a 4.80% beneficial ownership stake in Larimar Therapeutics, Inc. common stock.

Janus Henderson Group plc has reported a 0.0% beneficial ownership in Larimar Therapeutics, Inc., indicating a full divestment of its previous holdings.